Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trial

JAMA

Volumn 291, Issue 3, 2004, Pages 317-324

  Tariot, Pierre N ^a   Farlow, Martin R ^b   Grossberg, George T ^c   Graham, Stephen M ^d   McDonald, Scott ^d   Gergel, Ivan ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FALLING; FECES INCONTINENCE; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE INCONTINENCE;

EID: 0345872128     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.3.317     Document Type: Article

References (26)

1. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron. 1991;6:487-498.
2. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287:2335-2338.
3. Hebert LE, Scherr PA, Bienias JL, Bennett BD, Evans DA. Alzheimer's disease in the US population. Arch Neurol. 2003;60:1119-1122.
4. Dysken MW, Mendels J, LeWitt P, et al. Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type. J Am Geriatr Soc. 1992;40:503-506.
5. Laake K, Oeksengaard AR. D-cycloserine for Alzheimer's disease. Cochrane Database Syst Rev. 2002; (2): CD003153.
6. Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
7. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
8. Hartmann S, Möbius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol. 2003;18:81-85.
9. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7:486-488.
10. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S51-S56.
11. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery: a neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41-45.
12. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11 (suppl 2):S33-S39.
13. Galasko DR, Schmitt FA, Jin S, et al. Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging. 2000;21(suppl 1):S168.
14. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11 (suppl 2):S22-S32.
15. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
16. van der Kam P, Mol F, Wimmers M. Beoordelingsschaal voor Oudere Patienten (BOP). Deventer, the Netherlands: Van Loghum Slaterus; 1971.
17. Sclan SG, Reisberg B. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992;4(suppl 1):55-69.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987.
19. Wenk GL, Quack G, Moebius H-J, Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000,66:1079-1083.
20. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology. 1999;38:735-767.
21. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev. 1997;21:455-468.
22. Periclou A, Ventura D, Sherman T, Rao N, Abramowitz W. A pharmacokinetic study of the NMDA receptor antagonist memantine and donepezil in healthy young subjects [abstract]. J Am Geriatr Soc. 2003;51:S225.
23. Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).Int Clin Psychopharmacol 2002;17:297-305.
24. Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839.
25. Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:421-430.
26. Winblad B, Möbius HJ, Stöffler A. Glutamate receptors as a target for Alzheimer's disease: are clinical results supporting the hope? J Neural Transm Suppl. 2002;62:217-225.